Roivant Sciences Ltd.
ROIV
$36.36
$0.060.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -67.58% | -71.57% | -56.36% | -45.13% | -35.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -67.58% | -71.57% | -56.36% | -45.13% | -35.86% |
| Cost of Revenue | 26.25% | 25.13% | 24.08% | 29.14% | 31.71% |
| Gross Profit | -30.16% | -30.57% | -29.23% | -35.54% | -37.76% |
| SG&A Expenses | -6.55% | -6.12% | 27.40% | 26.84% | 80.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.45% | 8.14% | 25.77% | 27.96% | 54.18% |
| Operating Income | -9.87% | -10.13% | -28.28% | -30.91% | -58.32% |
| Income Before Tax | 68.87% | 61.18% | -59.12% | -118.01% | -119.43% |
| Income Tax Expenses | 205.24% | 176.77% | 1,318.16% | -13.69% | 28.53% |
| Earnings from Continuing Operations | 57.35% | 45.47% | -75.77% | -118.90% | -120.42% |
| Earnings from Discontinued Operations | -- | -- | -100.00% | 426.88% | 297.95% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -24.89% | -46.88% | 15.60% | 40.60% | 65.28% |
| Net Income | 45.73% | -74.30% | -593.91% | -107.77% | -110.36% |
| EBIT | -9.87% | -10.13% | -28.28% | -30.91% | -58.32% |
| EBITDA | -10.80% | -11.19% | -29.75% | -32.51% | -61.58% |
| EPS Basic | 45.59% | -84.69% | -751.06% | -109.22% | -111.82% |
| Normalized Basic EPS | -44.84% | -70.51% | -93.60% | -73.21% | -83.78% |
| EPS Diluted | 23.83% | -145.26% | -743.03% | -109.89% | -112.59% |
| Normalized Diluted EPS | -36.95% | -62.47% | -95.55% | -77.25% | -88.46% |
| Average Basic Shares Outstanding | -1.58% | -4.86% | -7.72% | -9.22% | -8.48% |
| Average Diluted Shares Outstanding | 2.29% | -2.60% | -9.11% | -11.79% | -11.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |